Understanding CBD Oil: The Science of the Endocannabinoid System

Author: Rohan Smith | Functional Medicine Practitioner | Adelaide, SA

Quick Answer: What Is CBD Oil?

Cannabidiol (CBD) is one of over 100 naturally occurring cannabinoids found in the cannabis plant. Unlike tetrahydrocannabinol (THC), CBD is non-intoxicating and does not produce a “high.” Instead, it interacts with the body’s own Endocannabinoid System (ECS), a regulatory network involved in maintaining balance across the nervous, immune, and gastrointestinal systems (1,2).

Core Concept: The Endocannabinoid System Explained

The Endocannabinoid System is a signalling network composed of receptors, endogenous cannabinoids (endocannabinoids), and enzymes responsible for their synthesis and breakdown. Its primary role is homeostasis—the ability of the body to adapt and maintain internal stability under stress.

CB1 and CB2 Receptors

CB1 receptors are predominantly located in the central nervous system and influence processes such as pain perception, memory, and mood. THC binds directly to CB1 receptors, accounting for its psychoactive effects (2).

CB2 receptors are expressed mainly on immune cells and within the gastrointestinal tract. These receptors play a role in immune modulation and inflammatory signalling, making them of interest in research involving the gut microbiome and intestinal inflammation (3).

How CBD Differs From THC

CBD does not bind directly to CB1 or CB2 receptors. Instead, it influences ECS tone indirectly, including inhibition of fatty acid amide hydrolase (FAAH), the enzyme responsible for breaking down the endocannabinoid anandamide. By slowing anandamide degradation, CBD may support endogenous regulatory signalling without intoxicating effects (1,11).

Beyond Cannabinoid Receptors

CBD is considered a multi-target compound due to its interaction with several non-cannabinoid pathways.

Serotonin (5-HT1A) Signalling

CBD has been shown to interact with the 5-HT1A serotonin receptor, a pathway involved in mood regulation, stress response, and nausea. This mechanism is frequently discussed in research exploring nutritional and neurobiological factors influencing mood (5,14).

Pain and TRPV-1 Receptors

CBD also interacts with transient receptor potential vanilloid type-1 (TRPV-1) receptors, which are involved in nociception and inflammatory pain signalling. This pathway has been examined in studies of neuropathic pain and chronic inflammation and fatigue patterns (4).

PPAR Activation and Cellular Signalling

Peroxisome proliferator-activated receptors (PPARs) regulate lipid metabolism, inflammation, and cellular differentiation. CBD-mediated PPAR activation has been explored in experimental models related to neuroinflammation and oxidative stress (6,12).

Solution / Test: Accessing CBD in Australia

In Australia, CBD is classified as a Schedule 4 (Prescription Only) medicine. Access typically occurs via the Therapeutic Goods Administration (TGA) Special Access Scheme (SAS-B) or through an Authorised Prescriber. Clinical oversight is required to ensure legal sourcing, appropriate dosing, and product quality (7).

When to Consider a Professional Review

CBD research is evolving, and responses may vary depending on individual biochemistry, concurrent medications, and underlying health patterns. Professional guidance is particularly important for individuals with complex inflammatory, neurological, or immune-related presentations.

Next Steps

CBD is best viewed as one potential component within a broader functional and nutritional medicine framework. Understanding regulatory status, biological context, and individual suitability is essential before considering use.

Key Insights

• CBD is non-intoxicating and interacts indirectly with the Endocannabinoid System (1,11).
• Its effects involve multiple pathways, including serotonin and TRPV-1 signalling (4,5).
• CB2 receptor activity links the ECS to immune and gut-related processes (3).
• Regulatory oversight and clinical guidance are essential in Australia (7).

Explore a Holistic Approach to Health

CBD is only one aspect of a comprehensive functional medicine approach. If you are exploring underlying contributors to chronic inflammation, mood dysregulation, or complex health patterns, professional guidance can help place emerging therapies into proper context.

Learn more or book a consultation at Elemental Health and Nutrition.

References

1. Pertwee RG. The diverse CB1 and CB2 receptor pharmacology of three plant cannabinoids: Δ9-tetrahydrocannabinol, cannabidiol and Δ9-tetrahydrocannabivarin. Br J Pharmacol. 2008 Jan;153(2):199-215. https://doi.org/10.1038/sj.bjp.0707442
2. Alger BE. Getting high on the endocannabinoid system. Cerebrum. 2013 Nov-Dec;2013:14. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3879657/
3. Wright K et al. Cannabinoid CB2 receptors in the gastrointestinal tract: a regulatory system in health and disease. Br J Pharmacol. 2008 Jan;153(2):263-70. https://doi.org/10.1038/sj.bjp.0707486
4. Costa B et al. The non-psychoactive cannabis constituent cannabidiol is an orally effective therapeutic agent in rat chronic inflammatory and neuropathic pain. Eur J Pharmacol. 2007 Feb 5;556(1-3):75-83. https://doi.org/10.1016/j.ejphar.2006.11.006
5. Russo EB et al. Agonistic properties of cannabidiol at 5-HT1A receptors. Neurochem Res. 2005 Aug;30(8):1037-43. https://doi.org/10.1007/s11064-005-6978-1
6. Scuderi C et al. Cannabidiol in medicine: a review of its therapeutic potential in CNS disorders. Phytother Res. 2014 Mar;28(3):291-300. https://doi.org/10.1002/ptr.4999
7. Therapeutic Goods Administration. Medicinal cannabis: Guidance for health professionals. Australian Government Department of Health and Aged Care; 2023 (updated). https://www.tga.gov.au/products/unapproved-therapeutic-goods/medicinal-cannabis-hub/medicinal-cannabis-guidance-documents
8. Arkell TR et al. Detection of Δ9-THC in oral fluid following vaporized cannabis with varying CBD:THC ratios. Drug Test Anal. 2019 Aug;11(8):1195-1204. https://doi.org/10.1002/dta.2605
9. Devinsky O et al. Cannabidiol: pharmacology and potential therapeutic role in epilepsy and other neuropsychiatric disorders. Epilepsia. 2014 Jun;55(6):791-802. https://doi.org/10.1111/epi.12631
10. Iffland K, Grotenhermen F. An update on safety and side effects of cannabidiol: a review of clinical data and relevant animal studies. Cannabis Cannabinoid Res. 2017;2(1):139-154. https://doi.org/10.1089/can.2016.0034
11. Blessing EM et al. Cannabidiol as a potential treatment for anxiety disorders. Neurotherapeutics. 2015 Oct;12(4):825-36. https://doi.org/10.1007/s13311-015-0387-1
12. Esposito G et al. Cannabidiol reduces Aβ-induced neuroinflammation and promotes hippocampal neurogenesis through PPARγ involvement. PLoS One. 2011 Dec 19;6(12):e28668. https://doi.org/10.1371/journal.pone.0028668
13. De Petrocellis L et al. Effects of cannabinoids and cannabinoid-enriched Cannabis extracts on TRP channels and endocannabinoid metabolic enzymes. Br J Pharmacol. 2011 Aug;163(7):1479-94. https://doi.org/10.1111/j.1476-5381.2010.01166.x
14. Campos AC et al. The anxiolytic effect of cannabidiol on chronically stressed mice depends on hippocampal neurogenesis: involvement of the endocannabinoid system. Int J Neuropsychopharmacol. 2013 Jul;16(6):1407-19. https://doi.org/10.1017/S1461145712001502
15. Zhornitsky S, Potvin S. Cannabidiol in patients with treatment-resistant epilepsy: an open-label interventional trial. Lancet Neurol. 2016 Mar;15(3):270-8. https://doi.org/10.1016/S1474-4422(15)00379-8